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Abstract
Background
Genetic programming (GP) is an evolutionary computing methodology capable of identifying
complex, non-linear patterns in large data sets. Despite the potential advantages of GP over
more typical, frequentist statistical approach methods, its applications to survival analyses
are rare, at best. The aim of this study was to determine the utility of GP for the automatic
development of clinical prediction models.
Methods
We compared GP against the commonly used Cox regression technique in terms of the
development and performance of a cardiovascular risk score using data from the SMART
study, a prospective cohort study of patients with symptomatic cardiovascular disease.
The composite endpoint was cardiovascular death, non-fatal stroke, and myocardial
infarction. A total of 3,873 patients aged 19–82 years were enrolled in the study 1996–
2006. The cohort was split 70:30 into derivation and validation sets. The derivation set was
used for development of both GP and Cox regression models. These models were then
used to predict the discrete hazards at t = 1, 3, and 5 years. The predictive ability of both
models was evaluated in terms of their risk discrimination and calibration using the valida-
tion set.
Results
The discrimination of both models was comparable. At time points t = 1, 3, and 5 years the
C-index was 0.59, 0.69, 0.64 and 0.66, 0.70, 0.70 for the GP and Cox regression models
respectively. At the same time points, the calibration of both models, which was assessed
using calibration plots and the generalization of the Hosmer-Lemeshow test statistic, was
also comparable, but with the Cox model being better calibrated to the validation data.
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Conclusion
Using empirical data, we demonstrated that a prediction model developed automatically by
GP has predictive ability comparable to that of manually tuned Cox regression. The GP
model was more complex, but it was developed in a fully automated way and comprised
fewer covariates. Furthermore, it did not require the expertise normally needed for its deriva-
tion, thereby alleviating the knowledge elicitation bottleneck. Overall, GP demonstrated con-
siderable potential as a method for the automated development of clinical prediction models
for diagnostic and prognostic purposes.
Introduction
Prognosis is central to medicine. All diagnostic and therapeutic actions aim to improve prog-
nosis [1]. Physicians and health policy makers need to make predictions on the disease prog-
nosis to support their decision making. Traditionally, clinical predictions have been more
implicit in their nature. Today, however, we live in an era of evidence-based medicine, which
is defined as "the conscientious, explicit and judicious use of current best evidence in making
decisions about the care of individual patients" [2]. Evidence-based medicine applies scientific
methods to clinical practice in order to improve the quality of patient care [3]. Patients them-
selves are involved in their care through shared decision making, where both physicians and
patients actively participate in making choices about diagnostic tests and therapeutic interven-
tions [1, 4].
Clinical prediction models may provide the evidence-based input for shared decision mak-
ing by estimating probabilities of risks and benefits associated with available choices [5]. Clini-
cal prediction models are also referred to as clinical prediction rules, prognostic models,
predictive risk models, or risk scores [6]. They combine a variety of characteristics (e.g. fea-
tures related to a patient, disease or treatment) to predict some diagnostic or prognostic out-
come [1]. Electronic health records store such characteristics in a digital format, thereby
facilitating the application of prediction research in clinical practice [7]. Statistical analyses are
commonly applied to such data to support individual predictions by population-based evi-
dence. In particular, one branch of statistics is commonly used in this context.
Survival analysis is a collection of statistical procedures for the analysis of data in which the
outcome of interest (i.e. survival outcome) is the expected duration of time until an event hap-
pens (or, for short, time to event), which is typically referred to as survival time [8]. In the clin-
ical context, survival analysis involves the estimation of the distribution of the time it takes for
an event (e.g. death, disease incidence or recurrence) to happen to a patient based on some set
of features, which are also known as explanatory variables, predictors or covariates. An impor-
tant characteristic of survival data is that the follow-up of patients is typically incomplete [1].
For example, some patients may have been followed for 5 days, some for 15 days, etc., yet we
may be interested in predicting 30-day survival. Such incomplete data are what we call censored
data. In essence, censoring occurs when we have some information about individual survival
times, but we do not know the survival time exactly in all subjects.
Traditionally the Kaplan-Meier (KM) method, a non-parametric approach, has been
used for exploratory analysis of survival data. Using the KM method, survival curves can be
generated for various subgroups (e.g. females versus males) to investigate the effects of explan-
atory variables on survival. However, the KM is unable to consider the effect of multiple
Genetic programming for clinical prediction
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explanatory variables simultaneously. To overcome this limitation, several regression model-
ling approaches have been proposed to enable prediction of time to event in the presence of
censored data [9]. Most of these models come from the long-established statistical literature
such as parametric survival models, including the Weibull, lognormal and Gompertz models
as well as the semi-parametric proportional hazards model proposed by Cox [10]. Hereafter,
these will be jointly referred to as linear statistical models. In medical and epidemiological
studies, the Cox proportional hazards model (or, for short, Cox regression) is the most preva-
lently used model for survival outcomes.
Alternative methods for survival analysis are based on machine learning, e.g. artificial neu-
ral networks (ANN). Multiple studies have compared such novel non-linear statistical methods
with their classic linear counterparts for survival analysis [11–14]. However, the results are
mixed as to whether these non-linear methods offer improved performance. For example,
Schwarzer et al. [15] reviewed a substantial number of studies that used ANNs in the diagnos-
tic and prognostic classification, concluding that there is no evidence so far that application of
ANNs represents real progress in the field of diagnosis and prognosis in oncology. Schwarzer
[15] reviewed a number of these comparison studies showing that the majority have claimed
equal performance, but could not rule out the possibility of bias. Another important argument
against the use of machine learning for survival analysis is that, with few exceptions (e.g. deci-
sion tree learning [16]), the learnt relationships between predictors and outcome are typically
non-transparent. This makes them difficult to validate by clinicians, which in turn leads to
poor adoption in clinical practice.
The main aim of this study is to develop a computational framework for automatically
deriving clinical prediction models from survival data. In line with traditional multi-variate
statistical modeling [17], the key requirement for an automatically derived model is to allow
survival to be assessed with respect to several factors simultaneously as well as offer estimates
of the strength of effect for each factor. These requirements imply that the model needs to be
explicit and potentially non-linear. Genetic programming (GP) is an evolutionary computa-
tion methodology designed to produce such models.
GP is inspired by population genetics and evolution at the population level as well as the
Mendelian understanding of the structure and mechanisms [18–20]. It solves complex prob-
lems automatically without requiring the user to know or specify the form or structure of the
solution in advance [21]. This makes GP well suited to symbolic regression, where, in addition
to searching for the solution to the complex associations between predictors and outcome, GP
also searches for the optimal model structure. This in turn makes GP well suited to prediction,
primarily an estimation problem, where the mutual correlations between predictors and the
outcome are to be estimated. GP has been shown to work well for recognition of structures in
large data sets and has the intrinsic advantage of automatically selecting features during the
evolutionary process [22, 23].
Having no predefined model structure, GP is able to represent complex non-linear associa-
tions that could not be achieved using linear regression techniques, and, therefore, may
achieve higher predictive accuracy. In fairness, the flexibility of regression models can also be
enhanced through the use of fractional polynomials, restricted cubic splines and interaction
terms, potentially increasing its predictive accuracy [7, 24–26]. However, this is not normally
used in practice as it complicates interpretation of the model. In addition, the correct use of
the appropriate regression methods requires extensive statistical knowledge [27].
GP may improve the selection and transformation of predictors, and it may lead to models
with good predictive accuracy in new patients [7, 28–31]. Despite its potential, critics state that
GP is more prone to over-fitting compared to conventional development methods [29]. On
the other hand, GP has got a clear advantage over other machine learning methods in the fact
Genetic programming for clinical prediction
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that it produces an explicit "white box" model, thus potentially leading to higher adoption rate
in clinical applications.
GP has been used in medical research for classification and, to a lesser extent, prediction.
The objective of this study is to assess its value for prediction on censored data for the purposes
of survival. This objective is two-fold. Given that GP is a general methodology for the develop-
ment of mathematical models rather than a specific technique for solving specific problems,
we first need to design and implement a GP approach specifically for survival analysis. This
entails development of suitable representation of survival data and the methods for evolving
survival models as well as evaluating their ‘fitness’. To investigate the practical utility of the GP
approach for survival analysis, we compared it against multi-variable Cox regression. Our case
study focuses on the development of a clinical prediction model for the occurrence of vascular
events in patients with symptomatic cardiovascular disease. We used data from a prospective
cohort study (described in Section II) to develop two prediction models, one using Cox regres-
sion and the other using GP (both described in Section III). Their performance was evaluated
in terms of risk discrimination and calibration. These results are reported in Section IV and
discussed in Section V.
Materials
Data
This study was carried out using data from the Second Manifestations of ARTerial disease
(SMART) study. Details of the ongoing prospective cohort study at the University Medical
Centre Utrecht, the Netherlands, designed to identify predictors of future cardiovascular
events in patients with symptomatic cardiovascular disease had been described previously
[32]. Briefly, we considered a total of 3,873 patients who were enrolled in the study between
September 1996 and March 2006. Newly referred patients with a clinical manifestation of ath-
erosclerosis, defined as transient ischaemic attack, ischaemic stroke, peripheral atrial disease,
abdominal aortic aneurysm (AAA) or coronary heart disease were enrolled when presenting at
hospital. Following an informed consent, patients underwent baseline examination, which
involved a standardized vascular screening, including a health questionnaire for clinical infor-
mation, laboratory assessment, and anthropometric measurements. All cohort members were
followed for clinical cardiovascular events for a minimum of three years. During follow-up,
patients were asked to fill in a questionnaire on hospitalizations and outpatient clinic visits
biannually. When a possible event was reported by a participant, correspondence and relevant
data were collected (discharge letters, laboratory radiology results). Based on all information
obtained, every event was audited by three physicians from different departments.
The primary outcome was a cardiovascular event, which was defined as cardiovascular
death, non-fatal stroke or non-fatal myocardial infarction. Combing predictor events is a com-
mon approach in cardiovascular research to increase statistical power [1]. A cardiovascular
event occurred in 460 patients during follow-up.
For our study we a priori selected 25 candidate predictors based on previous prognostic
studies [33, 34]. These 25 candidate predictors included risk factors traditionally associated
with future events (hyperhomocysteinemia, intima media thickness (IMT) and creatinine
level), demographics (age and sex) and risk factors for vascular events in the general popula-
tion (smoking, alcohol use, body mass index (BMI), diastolic and systolic blood pressure, lipids
and diabetes). Indicators to the location of symptomatic vascular disease (cerebral, coronary,
peripheral atrial disease or AAA) and markers of the extent of atherosclerosis (homocysteine,
glutamine, creatinine, albumin, IMT and presence of carotid artery stenosis, see Table 1) were
also considered as they may be relevant for future events in patients with symptomatic vascular
Genetic programming for clinical prediction
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Table 1. Baseline characteristics of patients in the SMART cohort.
Predictor Unit N Test set
N = 1,291
Training set
N = 2,582
Test statistic
Cardiovascular event 3873 11% (147) 12% (313) w2
1
¼ 0:45, P = 0.511
Gender: Female 3873 25% (320) 25% (656) w2
1
¼ 0:18, P = 0.681
Age years 3873 52 60 68 52 60 68 F1,3871 = 0.03, P = 0.86
2
Smoking: Never 3873 18% (235) 18% (458) w2
3
¼ 5:6, P = 0.131
Former 69% (885) 71% (1826)
Current 12% (158) 11% (286)
NA 1% (13) 0% (12)
Packyears years 3852 5.2 18.2 33.8 6.1 19.5 34.5 F1,3850 = 0.79, P = 0.38
2
Alcohol: Never 3873 20% (255) 19% (496) w2
3
¼ 1:1, P = 0.771
Former 11% (141) 10% (267)
Current 69% (885) 70% (1804)
NA 1% (10) 1% (15)
Body mass index Kg/m2 3870 24 26 29 24 26 29 F1,3868 = 3, P = 0.084
2
Diabetes: 0 3873 76% (983) 78% (2004) w2
2
¼ 1:1, P = 0.591
1 23% (294) 21% (552)
NA 1% (14) 1% (26)
Systolic blood pressure, automatic mm Hg 2650 127 140 155 127 139 153 F1,2648 = 1.4, P = 0.23
2
Diastolic blood pressure, automatic mm Hg 2652 73 79 86 73 79 86 F1,2650 = 0.01, P = 0.9
2
Systolic blood pressure, by hand mm Hg 2375 128 140 158 125 139 155 F1,2373 = 3.8, P = 0.052
2
Diastolic blood pressure, by hand mm Hg 2374 75 82 90 74 82 90 F1,2372 = 0.2, P = 0.65
2
Total cholesterol mmol/L 3855 4.4 5.2 5.9 4.3 5.1 5.9 F1,3853 = 2.6, P = 0.11
2
High-density lipoprotein cholesterol mmol/L 3843 0.95 1.15 1.40 0.97 1.18 1.43 F1,3841 = 3.8, P = 0.05
2
Low-density lipoprotein cholesterol mmol/L 3657 2.5 3.1 3.8 2.4 3.0 3.8 F1,3655 = 3.2, P = 0.073
2
Triglycerides mmol/L 3845 1.1 1.6 2.3 1.1 1.5 2.2 F1,3843 = 4.1, P = 0.042
2
Cerebral 3873 30% (387) 29% (760) w2
1
¼ 0:12, P = 0.731
Coronary 3873 56% (724) 56% (1436) w2
1
¼ 0:08, P = 0.781
Peripheral 3873 24% (308) 24% (632) w2
1
¼ 0:18, P = 0.671
Abdominal aortic aneurysm 3873 10% (134) 11% (282) w2
1
¼ 0:26, P = 0.611
Homocysteine (μ)mol/L 3410 10 13 16 10 13 16 F1,3408 = 2.5, P = 0.112
Glutamine (μ)mol/L 3854 5.3 5.8 6.5 5.3 5.7 6.5 F1,3852 = 0.94, P = 0.332
Creatinine mL/min 3856 78 89 102 78 89 101 F1,3854 = 0.62, P = 0.43
2
Albumin: No 3873 75% (969) 75% (1928) w2
3
¼ 1:1, P = 0.781
Micro 17% (221) 17% (434)
Macro 3% (33) 3% (81)
NA 5% (68) 5% (139)
Intima media thickness Mm 3775 0.75 0.88 1.05 0.75 0.88 1.07 F1,3773 = 0.24, P = 0.63
2
Presence of carotid artery stenosis: 0 3873 79% (1020) 79% (2038) w2
2
¼ 0:91, P = 0.631
1 18% (236) 19% (486)
NA 3% (35) 2% (58)
Numbers formatted a b c represent the lower quartile, the median, and the upper quartile for continuous variables. N is the number of non–missing values. Numbers
after the percent sign are frequencies. NA represents missing value. Tests used:
1Pearson test
2Wilcoxon test
https://doi.org/10.1371/journal.pone.0202685.t001
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disease. We note that the primary focus of these models is achieving accurate predictions
rather than insight into the predictor effects.
The data set were split randomly into two parts: a derivation set of approximately 66.67%
(2,582 patients) and a validation set of approximately 33.33% (1,291 patients). The derivation
set was used for model development (both by Cox regression and by GP), whereas the valida-
tion set was used to assess the performance of the two models. The aim of both models was to
predict the absolute risk of occurrence of a cardiovascular event. Given the availability of fol-
low-up data, 1-, 3-, and 5-year risks could be assessed. At least 10–20 events per candidate
predictor were proposed in previous guidelines for the sensible development of predictions
models [1, 25, 35, 36]. Therefore, with respect to sample size in the derivation set, the balance
of 313 events and 25 predictors was reasonable (see Table 1).
Missing values
We pre-processed the data in order to deal with the missing values. Multiple imputation is a
technique that offers substantial improvements over value replacement approaches based on
complete cases or cases matched for age and sex [37]. It involves creating multiple copies of
the data and imputing plausible values randomly selected from their predicted distribution.
Here, we used multiple imputation to replace missing values for smoking status, packyears,
alcohol, BMI, diabetes, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cho-
lesterol (TC), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL), tri-
glycerides, homocysteine, glutamine, creatinine, albumin, IMT and carotid artery stenosis (see
Table 1), generating a total of five imputed data sets. The first set of imputations was used for
further analysis (‘single imputation’). Although multiple imputation is preferable from a theo-
retical view point, single imputation was considered more practical and sufficient to obtain
reasonable predictions [1]. Final models were constructed with multiple imputed data sets to
check for any relevant differences in point estimates and widening of confidence intervals.
Methods
Cox regression
In medical and epidemiological studies, the Cox proportional hazards model (or Cox regres-
sion) is the most prevalently used model for survival outcomes [10]. The logistic model is anal-
ogous to this model for a binary outcome in uncensored data, where we know whether or not
the patient experienced the event in the time horizon of interest. Multi-variable logistic regres-
sion model is the most widely used statistical technique nowadays for binary medical outcomes
[1, 38, 39]. The Cox regression model is a natural extension of the logistic model in the survival
setting [1].
In the derivation set, we fitted a Cox regression model using a modelling strategy similar to
the one used for the development of a clinical prediction model on the SMART data set [1].
Briefly, we first fitted a full main effects model. Biologically implausible values were set to miss-
ing (prior to imputation) and extreme values truncated at the 1st and 99th centile. To enhance
the flexibility of the Cox regression and enable fairer comparison with the (unrestricted) GP,
we considered continuous predictors (e.g. age, creatinine, blood pressure) for transformation.
Several transformations were considered in adding polynomials, fractional polynomials, trans-
formations (e.g. logarithm, square root, exponential), restricted cubic splines (with varying
number of knots) and linear coding (i.e. categorization). To further enhance a fair comparison
with GP, we considered interaction effects between predictors.
Key limitations of the Cox regression model include (1) the assumption of proportional
hazards where hazard functions in the different strata are proportional over time, (2) the
Genetic programming for clinical prediction
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assumption of linearity and additivity which are implicit in regression’s linear combinations,
and (3) the fact that the baseline hazard is never specified. All model assumptions relevant to
the Cox regression model were tested. A reduced model was obtained by applying a backwards
selection procedure with Akaike information criterion (AIC) [40] as the stopping criterion.
Internal validation of the model was performed using a bootstrapping re-sampling proce-
dure [7, 24, 41]. Random samples were drawn (with replacement) from the derivation set with
200 replications, and the backwards selection of predictors for the reduced model repeated
each time. Bootstrapping yielded an estimate of optimism of the reduced models as expressed
by the concordance statistic, which for a binary outcome is identical to the area under the
receiver operating characteristic (ROC) curve. A shrinkage factor was derived from the boot-
strap estimates to re-calibrate the model to adjust for optimism. The re-calibrated model was
applied to the validation set to estimate its discrimination and calibration on an independent
sample. All analyses were carried out in R (v3.0.1) [42].
Genetic programming
Basic principles
GP is a search method inspired by the biological model of evolution [7, 43, 44]. It is an exten-
sion of the genetic algorithm first described by Holland [45] and Goldberg [46]. In GP, we
evolve populations of solutions represented as computer programs. Generation by generation,
GP stochastically transforms populations of solutions into new ones [21]. GP finds out how
well a solution performs by applying it, and then comparing its behavior to some ideal. This
comparison is quantified to give a numeric value called fitness. Based on some selection
scheme, those solutions (also known as individuals) that perform well are chosen to breed and
produce new solutions for the next generation. Genetic variation operators, namely crossover
and mutation, are used to create new solutions from existing ones [21]. Unlike genetic algo-
rithms, which only optimize the parameters of the model, GP evolves the actual structure of
the approximation model.
Various forms of GP differ in the ways in which an individual is represented. The most
common form of GP, tree-based GP, uses trees as its representation scheme. Consider, for
example, a tree shown in Fig 1, which corresponds to a mathematical expression that can be
used as a clinical prediction model. The leaves of the tree correspond to input (predictor) vari-
ables or constants. The internal nodes correspond to arithmetic operators, which represent the
building blocks (or genetic material) that will represent the potential solutions to the problem.
Over successive generations, the selection scheme, genetic operators and fitness function will
be applied to these building blocks to evolve individuals towards a suitable, hopefully optimal,
solution.
Implementation
For present analysis we used untyped steady-state single-objective tree-based GP [21, 43, 44] to
fit symbolic regression models to the data to estimate discrete hazard, thus predicting the risk
for cardiovascular events. Here the outcome is discrete hazard rate, which is the conditional
probability that a patient will experience the event during time interval [t– Δ/2, t + Δ/2), given
they are event-free at the beginning of the interval, as opposed to continuous hazard rate in the
Cox regression. An advantage of this model is not constrained by the assumption of propor-
tional hazards and is better suited to any non-linear interactions between explanatory vari-
ables. In our implementation of GP, a prediction model is a mathematical formula, without the
inherent restrictions in complexity found in regression methods such as Cox regression. All
predictors as considered inputs and feature selection are an inherent part of the evolutionary
Genetic programming for clinical prediction
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process. The modelling process starts with an initial set of candidate prediction models, which
are then iteratively optimized by selecting better models.
In the present study, an initial population of 1,000 different candidate models, i.e. different
mathematical formulas using different predictors were randomly created. The fit of all models
(to the training data) in the initial candidate set is calculated. Then in an iterative process:
1. A random sample (without replacement) is taken from the current set of models.
2. Genetic variation operators (crossover and mutation) are applied probabilistically to the
given subset of models to create new models.
3. The fitness is calculated for all newly created models.
4. The models in the current population are replaced by the newly created models that have
better fitness.
5. Steps 1–4 are repeated, until 12 hours of wall (clock) time has passed.
6. The model with the best fit to the holdout data from the final set of models is proposed as
the ‘final’ solution.
In each iteration, given two probabilistically selected models, crossover is realized by ran-
domly swapping parts of the model. Mutations occur by randomly replacing part of the model
with a randomly generated substitute. A prediction model developed by this type of GP can be
presented as a binary tree (see Fig 1 for an example). To limit the amount of optimism, the
trees were constrained in terms of complexity by restricting their depth to a maximum of 63
levels. The building blocks of the formulas are arithmetic operators chosen from +, –, /, ×, sin,
cos, tan,
p
, exp, and log. The output of the model is a vector of log odds for each subject and
time interval, which is subsequently used to predict the risk of the outcome (i.e. a cardiovascu-
lar event).
None of the well-studied fitness measures proved suitable for symbolic regression in the
presence of censored survival data. This is because unlike simple linear regression, where these
measures would be appropriate, there is no single continuous outcome with which to compare
its distance from a models estimate. Instead, in survival problems we have a two-part outcome,
with a continuous time until event value and a dichotomous event indicator value. In order to
Fig 1. The final model developed by genetic programming, presented as a binary tree.
https://doi.org/10.1371/journal.pone.0202685.g001
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develop a GP fitness function for survival data we take advantage of the fact that the hazard
function corresponds to a conditional probability in the discrete time domain. The following
equation defines the discrete-time hazard function, which is the conditional probability that
the individual i will experience the event within time period j for the first time given their par-
ticular values of the set of covariates, X, in that time period:
h^ðtij;XÞ ¼ P½Ti¼jjTij;X
This is in contrast to hazard in the continuous-time domain, which represents a rate, and as
such can take values greater than one. The corresponding discrete-time survival function is
defined as follows:
S^ðtij;XÞ ¼
Yj
k¼1
h^ðtij;XÞ
It follows that the original survival analysis problem can be cast into a classification problem
that requires the estimation of a conditional probability. However, to address the problem of
censoring, the data needs to be converted into the ‘counting process format’, in which there
are multiple rows per subject, one for each observed discrete-time interval. An example of
survival data in this format is given in Table 2, where X is a set of P covariates x1, . . ., xP. One
advantage of the ‘counting process format’, that it can inherently represent a combination of
time-varying covariates (e.g. cholesterol) as well as static covariates (e.g. gender).
We can now reformulate the discrete-time hazard function as the conditional probability
P(EVENT|X’), where X’ is a vector consisting of the original covariates found in X together
with an additional time period indicator j. This probability can be estimated using the likeli-
hood and prior ratios with a logistic link function:
h tij
 
¼
1
1þ e  ε
In the case where ε is a linear combination of covariates X’ (including time indicator j), this
represents a logistic regression model, which can be optimized using standard statistical tech-
niques such as Newton-Raphson method. The following equation defines εlp as a linear predic-
tor for discrete time survival analysis:
εlp ¼ ½a1D1ij þ a2D2ij þ    þ aJDJij þ ½b1X1ij þ b2X2ij þ    þ bPXPij
In this definition Dij is a ‘dummy’ time indicator, a dichotomy whose value indexes the
time period j in the i-th individual, P is the number of predictors (or covariates) and J is the
number of observed time periods.
However, if we adopt a more complicated relationship for ε using a symbolic expression,
we can model a non-linear relationship between hazard and covariates. It can be optimized by
Table 2. Example of survival data in the counting process format.
Patient Time Event x1 . . . xP
1 1 0 1 . . . 0
1 2 0 1 . . . 1
2 1 0 0 . . . 1
2 2 0 0 . . . 0
2 3 1 0 . . . 1
https://doi.org/10.1371/journal.pone.0202685.t002
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GP search operators, using the following likelihood function:
Yn
i¼1
YJi
j¼1
hðtijÞ
EVENTij 1   hðtijÞ
 1  EVENTij
Here, EVENTij is a dichotomy representing the event indicator of the i-th individual at the
j-th time interval. We define n as the number of subjects in training data and Ji as the number
of observed time periods the i-th individual contributes to the likelihood function. To make
optimization through the GP search operators more computationally tractable, we take the
logarithm of the likelihood to form a fitness function for survival analysis in censored data:
 
Xn
i¼1
XJi
j¼1
ðEVENTij log hðtijÞ þ ð1   EVENTijÞ log ð1   hðtijÞÞÞ
The fitness function expresses the joint probability of obtaining the data actually observed
on the subjects in the study as a function of the unknown population parameters.
Validation
To understand variable selection in the GP and enable comparison with bootstrapped back-
wards selection of the Cox model, the GP system was executed 25 times to produce a set of 25
models. For each iteration, the training data were randomly (stratified) split in a 2:1 ratio. The
final GP model was applied to the validation data set to assess its performance in terms of dis-
crimination and calibration on an independent sample.
We did not perform internal validation in the GP approach using a bootstrap as we did
with the Cox regression, because it would not have been possible to convert it into a shrinkage
factor in the same way as we would for a Cox regression. The GP system is a stochastic process,
with each run potentially yielding models with differing complex structures (i.e. symbolic
regression). As a result, regression coefficients do not exist in GP models in the same way that
they do in regression models. Instead the training data was split 2/3:1/3 into training and hold-
out sets, using a stratified random split to ensure proportionate number of events. The first 2/
3, the training set, was used for training to induce a population of prediction models. The
remaining 1/3, the holdout set, was used at the end of the GP run to calculate the fitness of the
population of models and thus determine the fittest or ‘best of run’ model to be returned as the
output of the GP system. In this way the final GP model was selected based on its fit to unseen
data using a sample other than the one it was trained on. All analyses were carried out in R ver-
sion 3.1.2 [42].
Results
Evaluation measures
The two clinical prediction models obtained from Cox regression and from GP, were evaluated
in terms of overall survival curves, discrimination and calibration in the validation data set.
The models were used to predict the discrete hazards h(t) at t = 1, 3, and 5 years. The models
were first evaluated by comparing the survival probabilities S(t) predicted by the models
against estimates obtained using the KM method. The agreement between these curves and
the KM estimates were assessed visually.
Discrimination is the ability of the risk score to differentiate between patients who did and
did not experience an event during the study period. This measure was quantified by calculat-
ing a concordance statistic (or C-statistic) proposed by Harrell et al. [24, 47–49], which is a
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rank-based measure for censored survival data. The C-statistic is an equivalent of the area
under the curve (AUC) measure [38] for survival data, in which 0.5 represents random chance
and 1 represents perfect discrimination. The C-statistic was evaluated considering truncation
of the survival/censoring times at t = 1, 3, and 5 years.
In the context of this study, calibration refers to how closely the predicted x-year cardiovas-
cular risk agrees with the observed x-year cardiovascular risk. Model calibration was assessed
using calibration plots and the generalization of the Hosmer-Lemeshow test statistic for sur-
vival data [50]. This was assessed by grouping subjects into g equally sized groups, with the
same cardinality, based on quantiles of predicted S(t), where t is a fixed time point, and calcu-
lating the ratio of predicted to observed cardiovascular risk. For each of the g groups, plotting
observed proportions (KM estimates) versus predicted probabilities (by the model) enabled
the calibration of the model predictions to be assessed visually. The closer the g points to the
45 degree line connecting (0,0) to (1,1), the better the calibration. To obtain the χ2 statistic,
the model predicted number of events was calculated, for each group, as the product of the
group size by the average predicted incidence 1 − S(t). The results were then compared to the
observed number of events in the corresponding groups calculated as the product of the group
size by the KM estimate of 1 − S(t). This leads to a statistic which, under the null hypothesis of
numerical agreement between predicted and observed number of deaths, has a χ2 distribution.
Calibration was evaluated by grouping subjects according to the predicted values of S(t) at
t = 1, 3, and 5 years. All analyses were carried out in R version 3.1.2 [42].
Descriptives
There were no major differences in the baseline characteristics of the patients between the der-
ivation and validation sets (see Table 1). Data were available on 9,636 and 4,895 person-years
collected during a median follow-up of 3.3 (0–9 years) and 3.3 years (0–9 years) for the deriva-
tion and validation sets respectively. In the derivation set, a total of 313 events occurred, corre-
sponding to 1-, 3-, and 5-year cumulative incidences of 4.1% (108), 8.9% (80), and 15.0% (84)
respectively. In the validation set, a total of 147 events occurred, corresponding to 1-, 3-, and
5-year cumulative incidences of 3.8% (50), 8.1% (36), and 12.0% (33) respectively.
Model derivation
Prior to modelling extreme values in IMT, BMI, lipids (cholesterol, HDL, LDL, triglycerides),
homocysteine and creatinine were truncated at the 1st and 99th centile. Indicators to the loca-
tion of symptomatic vascular disease (cerebral, coronary, peripheral atrial disease or AAA)
were optimally combined into a single variable (or sumscore), with each condition contribut-
ing one point except AAA that contributed 2 points. Using univariate Cox models, no signifi-
cant difference were found in the sumscore (χ2 119; 1 degree of freedom) using the separate
terms (χ2 123; 4 degrees of freedom). However, there was a saving of 3 degrees of freedom
from the sumscore.
The full Cox regression model consisted of 14 predictors, several of which had limited con-
tributions. Predictors that had a relatively large effect include age, location of symptomatic vas-
cular disease (sumscore), albumin, and creatinine. The coding of predictors that gave the best
representation for age and creatinine were (AGE– 50)2 and log(CREAT) respectively. We also
tested interactions between predictors, but the resultant interactions were not considered rele-
vant enough to include any interaction terms in the final model. The proportionality of haz-
ards was tested using an overall test which was not significant. We judged our sample size to
be large enough to allow for some model reduction (313 events and a full model with 17
degrees of freedom), facilitating easier practical application and clinical interpretation. We
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applied a backwards step-wise selection procedure using AIC as the stopping rule to obtain a
reduced Cox model. The reduced step-wise selected model was found to be optimal with 9 pre-
dictors (see Table 3). Predictors with relatively weaker effects (alcohol, diabetes, gender, smok-
ing status, and stenosis) were excluded from the reduced model. Bootstrapping of the reduced
model yielded an estimate of required shrinkage for the coefficients in the step-wise selected
model of 0.91, suggesting that each coefficient should be reduced by 9% to obtain a re-cali-
brated model that corrects for optimism. This shrinkage factor was applied to the reduced
backwards step-wise model and considered the calibrated ‘final’ Cox regression model (see
Table 4). All analyses were repeated with the multiple imputed data sets with similar results.
The final model produced by the GP model included 6 predictors: age (AGEn), sumscore of
previous atherosclerosis (HISTCAR2n), gender (SEXfemale.n), IMT (IMTn), homocysteine
(HOMOCn), and albumin (ALBUMINNo.n), in addition to the discrete time indicator (tj),
which was present in all GP models to represent the j-th time interval. The final prediction
model generated by GP is presented in Fig 1, which is a binary parse tree representing the fol-
lowing equation:
l^ tj;X
 
¼ Prob T ¼ tjjT  tj;X
 
¼
1
1þ e  Xb^
;
where
Xb^ ¼

tj   ð0:441þ tjÞ

 expðsinðsinðALBUMINNo:nÞÞÞ  expððHOMOCnþ AGEnÞ=tanð1:889ÞÞ
 cos

ðtanðSEXfemale:nÞ þHOMOCnþ AGEnÞ=exp

cos

ðtanðtanðexpðHISTCAR2nÞÞÞ þ sinðIMTnÞ
þ sinðIMTnÞÞ=tanð1:886Þ

 2:487   expðcosðHISTCAR2n=tanðtanð  1:813ÞÞ=tanðtanðtanð0:739ÞÞÞÞÞ
The GP approach was applied 25 times, each time trained and tested on a different stratified
re-sample of the derivation data set. This leads to a pool of 25 different ‘best of run’ models,
each of which may have selected different subset of predictors as inputs and as such may have
Table 3. Cox regression coefficients.
Predictor Variable Full Stepwise
Age AGE 0.0011 0.0011
Albumin ALBUMIN = Macro 0.5289 0.5371
ALBUMIN = Micro 0.5227 0.5184
Alcohol ALCOHOL = Current 0.0234
ALCOHOL = Former −0.1854
Body mass index BMI −0.0383 −0.0359
Creatinine CREAT 0.5992 0.5282
Diabetes DIABETES 0.0783
High-density lipoprotein cholesterol HDL −0.4619 −0.4096
Previous atherosclerosis (sum score) HISTCAR2 0.2980 0.2895
Homocysteine HOMOC 0.0169 0.0182
Intima media thickness IMT 0.5145 0.5879
Gender SEX = Female 0.1754
Smoking SMOKING = Current 0.0798
SMOKING = Former 0.0427
Presence of carotid artery stenosis STENOSIS 0.1815
Systolic, by hand SYSTH 0.0037 0.0041
https://doi.org/10.1371/journal.pone.0202685.t003
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differing levels of performance. In this pool of GP models, the mean number of predictors
used was 6, with interquartile range (IQR) 5–8. The backwards step-wise selection procedure
used in the Cox modelling was also repeated 25 times, using bootstrap re-sampling to better
understand the frequencies at which different subsets of predictors were selected. In the pool
of 25 backwards selected Cox models, the mean number of predictors used was 9 (IQR 8–10).
There was a reasonable association between the estimated effect of a predictor according in
the reduced backwards step-wise model and the frequency of the selection when the step-wise
selection was repeated in the bootstrap procedure.
D. MODEL VALIDATION. Using the validation data set, the average performance of the
25 ‘best of run’ prediction models automatically generated by GP was compared with the cali-
brated final Cox model. Graphical comparisons of the S(t) values produced by each model
with those obtained by the KM method in the validation set are shown in Fig 2. Both Cox and
GP models produced similar values that had good agreement with the KM estimates in the ear-
lier years. However, this agreement deteriorated in the latter years, where the KM estimates
have high variability as indicated by the large error bars. This high variation may be explained
by the fact that, with a median follow-up time of 3.3 years, there were far fewer events and
subjects in the latter time periods. Whilst the agreement deteriorated in the latter time-points,
both models had generally acceptable overall agreement.
The discriminative performance in the validation set, according to the C-statistic, of the
models at different time points is shown in Table 5 and Fig 3. The lowest estimate of the C-sta-
tistic was approximately 0.6, which implies that a satisfactory performance was observed in
both models at all time points. There was generally comparable discriminative performance of
both models at all time points, albeit in favor of the Cox model. Both models demonstrated
Table 4. Association of predictors with cardiovascular events.
Low High Δ Effect S.E. Lower
0.95
Upper
0.95
AGE 52.00 68.0 16.00 0.32 0.08 0.16 0.48
Hazard ratio 52.00 68.0 16.00 1.38 1.18 1.61
BMI 24.03 28.7 4.69 –0.15 0.08 –0.31 0.00
Hazard ratio 24.03 28.7 4.69 0.86 0.73 1.00
SYSTH 127.00 156.0 29.00 0.11 0.07 –0.04 0.25
Hazard ratio 127.00 156.0 29.00 1.11 0.96 1.29
HDL 0.96 1.4 0.47 –0.18 0.09 –0.34 –0.01
Hazard ratio 0.96 1.4 0.47 0.84 0.71 0.99
HISTCAR2 1.00 5.0 4.00 1.05 0.27 0.52 1.59
Hazard ratio 1.00 5.0 4.00 2.87 1.67 4.91
HOMOC 10.50 15.9 5.40 0.09 0.05 –0.02 0.19
Hazard ratio 10.50 15.9 5.40 1.09 0.98 1.21
CREAT 78.00 101.0 23.00 0.12 0.05 0.04 0.21
Hazard ratio 78.00 101.0 23.00 1.13 1.04 1.24
IMT 0.75 1.1 0.32 0.17 0.07 0.04 0.30
Hazard ratio 0.75 1.1 0.32 1.19 1.04 1.35
ALBUMIN—Micro:No 1.00 2.0 0.47 0.14 0.21 0.74
Hazard ratio 1.00 2.0 1.60 1.23 2.09
ALBUMIN—Macro:No 1.00 3.0 0.49 0.24 0.02 0.96
Hazard ratio 1.00 3.0 1.63 1.02 2.61
The calibrated final Cox model.
https://doi.org/10.1371/journal.pone.0202685.t004
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better performance at time t = 3 years, which may be explained by the 3.3 median follow-up
time in the validation set.
The calibration plots evaluated by grouping subjects according to quantiles of predicted
risk 1 − S(t) at t = 1, 3, and 5 years are shown in Fig 4. The corresponding χ2 statistics and p-
values are shown in Table 6. From the graphical inspection of the calibration plots, we can see
Fig 2. Average survival curves for the Cox regression and GP models. The error bars represent ±2 standard errors of the KM estimates.
https://doi.org/10.1371/journal.pone.0202685.g002
Table 5. C-statistic.
Time
(years)
Cox regression GP
1 0.66 0.59
3 0.70 0.69
5 0.70 0.64
Values estimates by the two models at t = 1, 3 and 5 years.
https://doi.org/10.1371/journal.pone.0202685.t005
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that there was no tendency to systematically over- or under-predict at any of the time points in
either Cox or GP models. The GP model was less calibrated than the Cox model, confirmed by
the higher χ2 values in Table 6 at times t = 3 and t = 5, whereas it was better calibrated at time
t = 1. Calibration in both models was worst at time t = 5, and best in the Cox and GP models at
times t = 3 and t = 1 respectively. However, the Homser-Lemeshow test statistic, detailed in
Table 6, suggested that there was only a statistically significant lack of calibration in the GP
model at time point t = 5.
Discussion
This study demonstrated that Cox regression and GP produced comparable results when eval-
uated on a common validation data set. After re-calibration, the discriminative ability of the
GP on the validation set was slightly larger than that of the Cox model at two time points,
whereas the Cox model was marginally better at only one time point. Despite slight relative
Fig 3. C-statistic estimates by model for t = 1, 3 and 5 years.
https://doi.org/10.1371/journal.pone.0202685.g003
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Fig 4. Calibration plots for the Cox regression and GP models at t = 1, 3 and 5 years.
https://doi.org/10.1371/journal.pone.0202685.g004
Table 6. χ2 statistic.
Time Cox regression GP
(years) χ2 p-value χ2 p-value
1 7.93 0.541 5.18 0.818
3 4.89 0.844 9.99 0.352
5 10.32 0.325 16.17 0.063
A comparison between observed and expected (according to the model) number of events in groups of patients
defined according to the predicted 1 − S(t) at t = 1, 3 and 5 years.
https://doi.org/10.1371/journal.pone.0202685.t006
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differences, both models demonstrated an acceptable level of discriminative ability (C-index
approximately 0.6 or higher) at all times points. The GP model had relatively poorer calibra-
tion when compared with the Cox model. The Cox model demonstrated no significant lack of
calibration at any time point. However, the GP model did demonstrate a significant lack of cal-
ibration at the latter time point only.
Selection
Despite generally comparable performance, albeit in favor of the Cox model, the predictors
selected for representing their relationship with the outcome were quite different. The final
reduced Cox model used 9 predictors, in contrast to 6 predictors used in the GP model. The
GP model used fewer predictors, further confirmed by repeating the GP and the stepwise
selection procedure used in the Cox modelling, resulting in mean numbers of predictors of 6
(IQR 5–8) and 9 (IQR 8–10) respectively. This finding suggests that GP may be better at repre-
senting the potentially non-linear relationship of (a smaller subset of) the strongest predictors.
Whilst considerable effort was made to relax the linearity of the Cox regression through trans-
formation of predictors, the nature of the approach relies on linear combinations of predictors.
The fact that GP required fewer predictors to achieve similar performance may have an advan-
tage in practical application of the developed clinical prediction model. The acquisition of
information that forms the inputs to such a model can be prohibitively onerous in routine clin-
ical practice. Therefore, a prediction model that requires fewer inputs, especially if the infor-
mation relating to these inputs is in practice recorded easily and to a good quality, would
considerably increase adoption and utility.
Interpretation
Unlike many other machine learning algorithms, GP in not a ‘black box’ method and pro-
vides an explicit mathematical formula as its output. However, the model structure in the
GP model is typically more complex than that of the Cox regression model. This hinders
the interpretation of the relative effects of predictors on the outcome. If the primary objec-
tive of the modelling is to understand these effects, such as in aetiologic research, then
Cox regression and other related approaches still remain the first choice. However, if the
primary goal of the research is an accurate risk prediction, then GP has some utility when
compared with its regression counterpart. GP offers advantages that include the ability to
learn complex non-linear relationships that may exist within the data. It is not constrained
by the statistical assumptions that underpin Cox regression (such as proportional hazards).
On the contrary, GP has inherent feature selection and develops models in a fully automated
fashion.
Optimism
An advantage of Cox regression is its ability to be calibrated using all data available by applying
a shrinkage factor, a measure of the model’s optimism (or over-fitting) estimated though boot-
strapping or penalized regression methods. On the other side, GP cannot estimate a shrinkage
factor in the same way and needs a validation sample. This suggests that in cases where the
data are scarce, Cox regression may be a better approach. By contrast, in cases where there the
data are abundant, possibly with a large number of predictors and potential interactions, GP
would have a distinct advantage. Whilst interaction effects can be modelled using regression
techniques, this can be onerous and requires significant statistical expertise.
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Expertise
The considerable statistical and clinical expertise required in the development of appropriate
clinical predictions should not be understated. Problems with step-wise feature selection meth-
ods are another concern; including biased R2 values, confidence intervals for effects and pre-
dicted values that are falsely narrow, biased regression coefficients that need shrinkage, and
severe problems in the presence of collinearity. Both Cox regression and step-wise selection
are widely used and widely abused in prognostic and aetiologic research. Whilst fitting models
using these techniques is relatively straightforward and intuitive, sometimes they are applied
blindly without appropriate testing of the underlying assumptions. Cox regression is a power-
ful tool, but its correct application requires a certain amount of statistical rigor and expertise
from the researcher, and cannot be used with certain data if its underpinning assumptions
are violated. Another weakness of a Cox model is that it does not explicitly define the underly-
ing baseline hazard, which means that, technically, its predictions are only valid at the time
points observed in the data and that it may not appropriate for extrapolation to non-observed
time points. It should be noted, however, that other regression methods for survival analysis,
such as parametric survival models, can define the baseline hazard and are appropriate for
extrapolation. However parametric modelling of survival is even more involved than Cox
modelling, requiring greater technical expertise, and as such features far less in published
aetiologic research.
Efficiency
The main weakness of the GP approach is that the data need to converted into the counting
process format (i.e. time-coded), which leads to large data sets and long executions times.
Whilst in theory GP works better on large data sets, the long execution times can make its use
prohibitive in practice. However, this weakness can be addressed though parallel processing.
GP is a method that can be described as naturally parallelizable, and as such can be adapted to
execute in parallel across multiple machines or processors.
Clinical context
This work has limitations introduced by its use of data from the SMART study, a study from
a secondary prevention setting, designed to predict the risk of subsequent cardiovascular
events in patients with already presenting with clinical cardiovascular disease. Through the
use of the SMART study data, this work has demonstrated the utility of GP in a secondary
prevention setting. However, there are limitations in the generalizability of these findings to
other clinical settings of cardiovascular risk prediction. Indeed, secondary prevention in sta-
ble cardiovascular patients is not the most common clinical setting for the application of car-
diovascular risk prediction models in routine practice. Further work is required to assess the
utility of GP for automated development of new clinical prediction models in other clinical
and environmental settings, preferably comparing their performance against more estab-
lished risk prediction models currently used in routine clinical practice, e.g. QRISK 2 [51]
and SCORE [52] for primary prevention of CVD, the GRACE score [53, 54] in acute coro-
nary syndromes and, euroSCORE [33] in cardiac surgery. Further work will also be required
to identify the most appropriate clinical parameters required for GP risk modelling in order
to optimize the predictive power in the relevant setting and to ensure that these required
measures are not only practical to measure at scale in routine clinical practice but also cost
effective.
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Parameters
Finally, the GP model has a number of parameters that need to be specified a priori. These
parameters include the size of the population of models, the building block of models such as
mathematical operators, the number of runs to perform, the rates at which to apply genetic
variation, and parameters such as maximum tree depth that control the complexity, and thus
potential of over-fitting of the final GP model. Often, the choice of these parameters is based
on trial and error, model tuning or existing literature. Model tuning refers to repeating the
same experiment many times whilst simultaneously varying multiple parameters and quantify-
ing relationship between them and the quality of resultant models to understand which param-
eters are important.
However, little or no literature discusses the relative importance of specific parameters of
survival analysis. Model tuning was outside of the scope of this study, but further research is
warranted into characterizing the association of GP parameters and performance in a survival
analysis setting. Our choice of starting parameters was driven by the size of the training data
available, the perceived relative complexity of the problem and, the recommendation and
guidelines from the relevant literature. Wherever possible we opted for the most common or
default operators and parameter settings, opting not to tune the parameters. The default set of
operators (namely, +, −,, ×, sin, cos, tan,
p
,exp, log) was used to enable the representation
of potential non-linear relationships present in the training data. Koza’s [44] ramped half-and-
half random initialization method, the most commonly used initialization operator in tree-
based GP. Some authors propose that, as a rule of thumb, to specify the maximum tree depth,
one should try to estimate the size of the expected solution size and add some percentage as a
safety margin. For this experiments we calculated, when transforming categorical predictors
into ‘dummy’ variables (i.e. n − 1 dummies per categorical predictors, where n is the number
of levels), that the expected solution depth would be 21 based on the expected solution being
modelled as a regression model with 19 predictors. Based on this we estimated a maximum
depth should be 21 × 3% = 63. In most real-world GP applications only a fixed compute time
budget is available. Therefore, the expiration of a fixed time compute budget was chosen as
the termination criterion. The compute time budget for these experiments was set to 12 hours
wall-time and these experiments were run on a single thread on an Intel Westmere 2.8GHz
CPU with 48GB of memory. Based on observations from GP practitioners, we opted for a rela-
tively large population size of μ = 1000, which tends to have suitable genetic diversity. The
most commonly used mutation and recombination operators in tree-based GP, subtree muta-
tion and subtree crossover were selected. Because of relatively high complexity of the problem
at hand, we set a relatively high genetic variation rate of 0.5 for both mutation and crossover.
Conclusions
The main aim of this study was to develop a computational framework for automatically deriv-
ing clinical prediction models from survival data. For this purpose, we used GP, an evolution-
ary computation methodology designed to derive explicit mathematical models from large
datasets. An obvious advantage of this approach in comparison with traditional machine
learning methods is the transparency of learnt relationships between predictors and outcome.
This makes it easier to be understood and validated by clinicians, thus improving the adoption
of machine learning approaches in clinical practice. Unlike multivariate statistical modelling,
which is routinely used in survival analysis, GP does not require the expertise (both clinical
and statistical) normally needed for model derivation, thereby alleviating the knowledge elici-
tation bottleneck. Having considered these advantages of GP, its suitability for survival analysis
depends crucially on the predictive ability of its survival models. Using empirical data, we
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demonstrated that a model developed automatically by GP has the predictive ability compara-
ble to that of manually tuned Cox regression. However, in terms of practical utility of the GP
approach for survival analysis, other properties of the two respective models need to be consid-
ered as well. For example, the complexity of the GP-derived model was found to be much
higher. While higher complexity may lead to higher accuracy, it may also reduce the transpar-
ency of a model by convoluting the effects of and relationships between individual predictors.
Fortunately, the complexity consideration can be embedded into the fitness function, and,
therefore, fully controlled.
To our knowledge, this is the first empirical study to assess the value of GP for clinical pre-
diction purposes compared to the well-known and widely applied Cox regression technique.
Whilst the highly tuned Cox regression model performed marginally better on the validation
data, both in term of calibration and discrimination, the performance of the automatically
generated prediction model was generally comparable. The comparable performance demon-
strates the utility of GP for clinical prediction modelling and prognostic research, where the
primary goal is accurate prediction. In etiological research, where the primary goal is to exam-
ine the relative strength of association between risk factors and the outcome, Cox regression
(and its variants) remains the de facto approach.
Further work is required to characterize relationship between GP parameters and the per-
formance of the resulting survival models, as is further research into reducing the execution
times through parallel processing. Finally, further validation is required to assess the utility of
GP for automated development of new clinical prediction models in other clinical and envi-
ronmental settings.
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